ViroPharma announced updated data from the two ongoing, Phase 2 dose ranging studies investigating maribavir for both first line treatment of cytomegalovirus viremia and treatment of resistant/refractory CMV. ViroPharma is currently conducting two Phase 2 dose ranging studies of oral maribavir at one of three doses in transplant recipients. The first is a randomized, active controlled maribavir dose blinded multicenter Phase 2 study in up to 160 European hematopoietic stem cell or solid organ transplant recipients who have demonstrated CMV viremia but do not have CMV organ disease. ViroPharma is also conducting a randomized, dose blinded multicenter Phase 2 study intended to enroll up to 120 hematopoietic stem cell or solid organ transplant recipients who have resistant or refractory CMV viremia with or without CMV organ disease. In both studies investigators have flexibility in determining duration of treatment depending on a subject's response. The resistant/refractory study has been conducted in the U.S. to date and is now being expanded to add additional EU sites.